Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 9
Submit an article Journal homepage
621
Views
5
CrossRef citations to date
0
Altmetric
Articles

A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia

Nicholas J. Shorta Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAORCID Iconhttps://orcid.org/0000-0002-2983-2738View further author information
ORCID Icon,
Gautam Borthakura Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAORCID Iconhttps://orcid.org/0000-0001-7679-6453View further author information
ORCID Icon,
Naveen Pemmarajua Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Courtney D. Dinardoa Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Tapan M. Kadiaa Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Elias Jabboura Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Marina Konoplevaa Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Walid Macarona Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAORCID Iconhttps://orcid.org/0000-0001-5168-0163View further author information
ORCID Icon,
Jing Ningb Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Junsheng Mab Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Sherry Piercea Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Yesid Alvaradoa Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Koji Sasakia Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAORCID Iconhttps://orcid.org/0000-0002-9140-0610View further author information
ORCID Icon,
Koichi Takahashia Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Zeev Estrova Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAORCID Iconhttps://orcid.org/0000-0002-1623-3613View further author information
ORCID Icon,
Lucia Masarovaa Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAORCID Iconhttps://orcid.org/0000-0001-6624-4196View further author information
ORCID Icon,
Ghayas C. Issaa Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Guillermo Montalban-Bravoa Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Michael Andreeffa Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Jan A. Burgera Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Darla Millera Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Lynette Alexandera Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Aung Naingc Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Guillermo Garcia-Maneroa Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Farhad Ravandia Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
&
Naval Davera Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USACorrespondence[email protected]
View further author information
 show all
Pages 2161-2170 | Received 22 Dec 2021, Accepted 30 Mar 2022, Published online: 20 Apr 2022

Citations (5)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

William L Redmond. (2023) Challenges and opportunities in the development of combination immunotherapy with OX40 agonists. Expert Opinion on Biological Therapy 23:9, pages 901-912.
Read now
Aleksandra Gołos, Joanna Góra-Tybor & Tadeusz Robak. (2023) Experimental drugs in clinical trials for acute myeloid leukemia: innovations, trends, and opportunities. Expert Opinion on Investigational Drugs 32:1, pages 53-67.
Read now

Articles from other publishers (3)

Gill Norman, Thomas Mason, Jo C Dumville, Peter Bower, Paul Wilson & Nicky Cullum. (2022) Approaches to enabling rapid evaluation of innovations in health and social care: a scoping review of evidence from high-income countries. BMJ Open 12:12, pages e064345.
Crossref
Maddalena Marconato, Joseph Kauer, Helmut R. Salih, Melanie Märklin & Jonas S. Heitmann. (2022) Expression of the immune checkpoint modulator OX40 indicates poor survival in acute myeloid leukemia. Scientific Reports 12:1.
Crossref
Tristan E. Knight, Holly Edwards, Soheil Meshinchi, Jeffrey W. Taub & Yubin Ge. (2022) “FLipping” the Story: FLT3-Mutated Acute Myeloid Leukemia and the Evolving Role of FLT3 Inhibitors. Cancers 14:14, pages 3398.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.